MASCC Guidelines and Assessment Tools
Clinical Practice Resources

• Antiemetic Guidelines
  The MASCC/ESMO Antiemetic Guidelines have been updated in English as of April, 2010. The guidelines are available in ten languages, obtained by the standard forward/backward translation process. Translations of the updated guidelines will be available soon.
• Mucositis Guidelines
  Mucositis: Perspectives & Clinical Practice Guidelines
  A major recent effort of the Mucositis Study Group of MASCC/ISOO has been a comprehensive review of the literature related to mucositis and the development of evidence-based clinical practice guidelines. The first set of MASCC/ISOO Mucositis Guidelines were based on literature published between January 1996 and May 2002. The original guidelines were published in the journal Cancer in 2004. In June 2005, panelists from the Mucositis Study Group met again to update these guidelines. These updates were based on a comprehensive and systematic evaluation of the literature published since May 2002. The updated guidelines were published in the journal Cancer in 2007.
• MASCC Antiemesis Tool (MAT)
  The MAT was first created and posted in 2004. It is now available in seven languages,obtained by the standard forward/backward translation process.
  The MAT is now validated, see Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L,Rittenberg C, Gralla RJ. Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis Tool. J Pain Symptom Manage. 2007 Aug; 34(2): 148-159.
  The MASCC Antiemesis Tool (MAT) was developed by members of MASCC to assist patients and oncology professionals in communicating accurately about the prevention and control of nausea and vomiting that may occur with chemotherapy. The concept of the MAT is to provide an easy-to-use and easy-to-evaluate tool to assist in providing the best individual care to patients. Additionally, the tool will aid treatment centers in understanding the effectiveness of their antiemetic strategies.
• MASCC Oral Agent Teaching Tool (MOATT)
  The MASCC Teaching Tool for Patients Receiving Oral Agents for Cancer (MOATT) was developed by MASCC members and evaluated and revised so that it may be used worldwide. It is available in several languages that were translated using the standard forward/backward translation process.
• MASCC EGFR Inhibitor Skin Toxicity Tool (MESTT)
  The MESTT was developed by the MASCC Skin Toxicity Study Group in 2008 as a tool to assist oncology health professions with the monitoring and reporting of dermatologic AEs in EGFRI-treated patients. The MESTT is an event-specific grading system that can be used to standardize assessment, optimize the use of EGFR inhibitors and enable researchers to conduct more informative, controlled studies in this patient population.